Study title:
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Br J Clin Pharmacol. 2003 Jan;55(1):86-93Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Br J Clin Pharmacol. 2003 Jan;55(1):86-93
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Anesthesia and Analgesia [E03]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: CHLORHEXIDINE AND LIDOCAINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|